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ABSTRACT
Immunochromatographic tests based on the recombinant antigen K39 represent a major 
advance in diagnosing visceral leishmaniasis (VL) in recent years. Some performance 
variations are expected and have occurred in the use of several commercial rapid tests, 
especially in different geographical settings. This is the first evaluation in the Americas of 
the test recently provided by the public health system in Brazil for the diagnostic of VL, the 
OnSite™ Leishmania IgG/IgM Combo. In this first clinical test evaluation, 113 VL-positive 
patient samples and 73 negative controls were tested and a sensitivity of 91.2% and specificity 
of 94.5% were observed. These results indicate the need for further analysis and comparisons 
with the performance of other available commercial tests in order to define the impact of this 
new test on the quality of VL diagnosis in Brazil. 
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INTRODUCTION
Rapid tests using the recombinant K39 antigen (rK39) represent a breakthrough 
in visceral leishmaniasis (VL) diagnosis in recent decades. This antigen is a 
39-amino acid repeat encoded by a kinesin-related gene of Leishmania chagasi, 
donovani-specific complex1. It has been used for detection of antibodies with 
high sensitivity and specificity, through different platforms. The Kalazar Detect™ 
(InBios International, USA) was the first rapid test provided by the Brazilian public 
health system in 2009. After its acquisition, the Kalazar Detect™’s performance 
was assessed, showing a sensitivity of 88.1% and specificity of 90.6%2. In 2015, 
the Kalazar Detect™ test was replaced by the IT LEISH® (BIO-RAD Laboratories 
Inc., France), a test previously validated in Brazil using capillary blood samples 
and presenting 93% sensitivity and 97% specificity3. In 2016, a study demonstrated 
that replacing the diagnostic test was economically correct because the 
IT LEISH® was a more cost-effective diagnostic strategy than the Kalazar Detect™ 
in Brazil4.
In 2017, another new rapid test became available in Brazil, the OnSite™ 
Leishmania IgG/IgM Combo test (CTK Biotech, USA). Although the new test 
has been standardized for use in serum and capillary blood samples, no data are 
available on its performance for diagnosing VL by L. infantum. Thus, despite being 
conducted after the purchase and distribution of the test by the public health system, 
this study aimed to evaluate the performance of the OnSite™ Leishmania IgG/IgM 
Combo test, for diagnosing VL in Brazil.
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MATERIAL AND METHODS
The serum samples used in this study were anonymized 
and are part of a historical collection of the Instituto Rene 
Rachou, a reference laboratory for leishmaniasis in Brazil, 
and their use was approved by the local Research Ethics 
Committee (Protocol Nº 44549915200005091). 
Samples of stored sera from 186 patients were tested. 
The age of patients ranged from 1 month to 70 years and 
62.3% of them are men (114/186). None of the patients had 
a diagnosis of HIV infection. Of these, 113 samples were 
from patients classified as VL cases (positive samples), 
whose diagnosis were confirmed by parasitological 
methods (bone marrow smear or culture). The remaining 
73 samples were from patients presenting characteristic 
signs and symptoms of VL but no Leishmania parasites 
on parasitological tests and they were diagnosed with 
other diseases (negative controls). The test was performed 
according to the manufacturer’s instructions and interpreted 
by three independent observers. Each observer was 
blinded with respect to the other’s readings and to the 
patient’s disease status (positive or negative). The OnSite™ 
Leishmania IgG/IgM Combo test differs from the other 
rapid tests because it detects both IgG and IgM antibodies. 
According to the manufacturer, the test is considered 
negative when only one red line appears (control line) 
and positive when the “M line” (indicating IgM antibody 
presence) or the “G line” (indicating IgG antibody presence) 
or both lines appear in addition to the control line. To 
account for all band reactivity possibilities, the analysis 
was performed considering two scenarios:
Scenario 1: the presence of at least one of the two 
reactive bands (IgG or IgM) define the test as positive, as 
recommended by the manufacturer; 
Scenario 2: the presence of a reactive IgG band defines 
the test as positive, independently of the IgM band result.
The test was evaluated using samples that were 
previously used to evaluate the IT LEISH® test a few years 
ago3; however, some patient’s samples were no longer 
available. Thus, two strategies were used to analyze the 
OnSite™ Leishmania IgG/IgM Combo’s performance: 
i) its performance was compared with that of IT LEISH®, 
considering only the samples tested for both tests; and 
ii) its performance was compared with that of IT LEISH® 
as reported for a larger sample by Machado de Assis et al.3.
In this analysis, the performance measures of interest 
were sensitivity, specificity and accuracy. Analyses were 
performed in the Open Source Epidemiologic Statistics 
for Public Health (OpenEpi) version 2.35. Exact binomial 
95% confidence limits (95% CI) were calculated for 
each performance measure. The comparison of OnSite™ 
Leishmania IgG/IgM Combo performance with the 
previously described performance of IT LEISH® was carried 
out by evaluating the confidence interval of the difference 
between the tests (using the chi-square test). The Kappa 
index was interpreted following criteria of Landis and Koch6 
to assess concordance among the observers and between the 
OnSite™ Leishmania IgG/IgM Combo and the IT LEISH® 
tests. A P value < 0.05 was considered statistically significant.
RESULTS
The OnSite™ Leishmania IgG/IgM Combo rapid 
test’s performance for the two proposed scenarios 
is presented in Table 1. Using the positivity criteria 
recommended by the manufacturer, the estimated sensitivity 
of the OnSite™ Leishmania IgG/IgM Combo was 91.2% 
(95% CI: 84.5-95.1%), which was the same sensitivity 
observed in Scenario 2 since no patient in the VL group 
presented isolated reactivity regarding the IgM band. The 
presence of the reactive “M line” was observed in only one 
sample in which no reactive “G line” was present (case details: 
a 28-year-old patient, negative by parasitological tests, was 
IT LEISH® negative and diagnosed with mycobacteriosis). 
Seven samples that tested positive by the OnSite™ Leishmania 
IgG/IgM Combo showed a low intensity band that required 
an external light source (flashlight). These samples were 
considered positive following the manufacturer’s instructions. 
Of these seven results, six were true-positives (samples 
from VL patients). Conversely, ten samples with a positive 
parasitological test were negative on the OnSite™ Leishmania 
IgG/IgM Combo, and of these, eight tested positive by 
IT LEISH®. These samples were rescreened with IT LEISH®, 
and the previous positive results were confirmed. 
Considering the positivity based on the presence of 
any reactive band, of the 73 negative samples, the OnSite™ 
Leishmania IgG/IgM Combo exhibited four false-positive 
results and a specificity of 94.5% (95% CI: 86.7-97.9%). 
These four samples (apparently false-positives on the 
OnSite™ test) were diagnosed as follows: bacterial sepsis, 
hepatic insufficiency, lymphoma and mycobacteriosis. Of 
these, two samples screened positive on the IT LEISH®, and 
one presented only the reactive “M line” on the OnSite™ 
Leishmania IgG/IgM Combo. Considering the test positivity 
as the IgG band presence, three false-positive results on the 
OnSite™ Leishmania IgG/IgM Combo test was observed, a 
specificity of 95.9% (95% CI: 88.6-98.6%).
Comparing the IT LEISH® and the OnSite™ Leishmania 
IgG/IgM Combo tests on the same tested samples, no 
significant differences were observed in sensitivity or 
specificity. The concordance rate between the OnSite™ 
Leishmania IgG/IgM Combo and the IT LEISH® by the 
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Kappa index was 0.88 (95% CI: 0.81-0.95) for Scenario 
1 and 0.89 (95% CI: 0.82-0.96) for Scenario 2. In both 
scenarios, the observers were in 100% agreement on the 
test interpretation (K = 1.0). Compared with the previously 
published IT LEISH® test performance3, the specificity of the 
OnSite™ Leishmania IgG/IgM Combo was lower (94.5%; 
95% CI: 86.7-97.9% versus 97%; 95% CI: 91.6-99%, 
p=0.04), with no difference in sensitivity between the tests. 
DISCUSSION
No consensus exists on the minimum performance 
parameters required for VL diagnostic tests. In addition to 
the severity of each disease, which determines the acceptable 
tolerance for misdiagnosis, this definition depends mainly on 
the level of technological development previously achieved 
for a given methodology, as reflected in the performance of 
similar products that are currently available. In VL cases, 
an ideal test meets the highest performance compared 
with others, along with affordable cost and operability, 
when it is feasible in places with low infrastructure in 
underdeveloped countries where the disease predominates. 
According to Boelaert et al.7, the minimum sensitivity and 
specificity rates required for a VL rapid diagnostic test 
would be 95% and 98%, respectively. However, there is 
no consensus on the minimum accepted performance for a 
VL screening test. In Brazil, for example, in the public call 
for the purchase of the new rapid test for VL, the minimum 
performance required for both sensitivity and specificity was 
90%8. Considering 95% for both sensitivity and specificity 
and the manufacturer’s positivity criteria for the OnSite™ 
Leishmania IgG/IgM Combo, the test performance would 
be considered unsatisfactory, while accepting 90% for the 
minimum required parameters, the same performance would 
be considered within the desired limits.
The manufacturer of OnSite™ Leishmania IgG/IgM 
Combo defines the test positivity based on either of the 
two bands (IgM or IgG), but this instruction could pose 
a problem. In the present study, IgM band reactivity was 
observed in only one case in which the reactive M line was 
a false-positive reaction in the serum sample from a patient 
clinically diagnosed with mycobacteriosis. The potential 
consequence of this observation, and the lower specificity 
observed for the OnSite™ Leishmania IgG/IgM Combo 
test compared with the VL rapid test previously available 
in Brazil (IT LEISH®), would be the increment of false 
VL diagnoses, that could lead to unnecessarily patients 
exposition to toxic leishmaniasis treatment options. For an 
indirect comparative analysis, it is important to consider 
data from some studies that evaluated the performance 
of rapid tests for VL in Brazil, published in recent years. 
The sensitivity and specificity reported for these tests 
were respectively: Kalazar Detect™: 88.1-95.5% and 
90.6-100%2,9,10; IT LEISH®:93-100% and 96.5-100%2,3,11 
and OrangeLife® (OrangeLife, Brazil): 88.9 and 94.7%10. 
Globally, results of the World Health Organization’s 
initiative addressing the performance of the available 
commercial rapid VL tests containing bound rK39 or 
rKE16 antigen in endemic regions should be considered12. 
On the Indian subcontinent, all tests performed well, with 
high sensitivity, ranging from 92.8% (95% CI: 88.9-95.4%; 
Crystal® KA) to 100% (95% CI: 97.9-100%; Signal® KA) 
and high specificity, ranging from 96.0% (92.8%–97.8%; 
Kalazar Detect™) to 100% (95% CI: 97.8-100%; Signal® 
KA)12. However, in East Africa and Brazil, lower sensitivity 
was observed, ranging from 36.8% (95% CI: 31.1-42.9%; 
Crystal® KA) to 92% (95% CI: 87.8-94.8%; IT LEISH®)12. 
IT LEISH®’s sensitivity was significantly better than any 
other products evaluated in East Africa (p< 0.0001) and 
Brazil (p= 0.013). The OnSite™ Leishmania IgG/IgM 
Combo test was not included in this global assessment 
while another test produced by the same manufacturer, the 
OnSite™ Leishmania Ab Rapid test, was evaluated only in 
India using samples from 250 VL-patients and 249 non-VL, 
Table 1 - Performance of the OnSite™ Leishmania IgG/IgM Combo test 
Studygroup
Scenario 1* Scenario 2**
Positive 
result
Negative 
result Total
Positive 
result
Negative 
result Total
Case 103 10 113 103 10 113
Non-case 4 69 73 3 70 73
Total 107 79 186 106 80 186
Sensitivity (%) (95%CI) 91.2 (84.5 – 95.1) 91.2 (84.5 – 95.1)
Specificity (%) (95%CI) 94.5 (86.7 – 97.9) 95.9 (88.6 – 98.6)
Accuracy (%) (95%CI) 92.5 (87.8 – 95.5) 93.0 (88.4 – 95.9)
*Scenario 1: The test was considered positive when there is at least one of the reactive bands (IgG or IgM), as recommended by 
the manufacturer; **Scenario 2: The test was considered positive when the reactive IgG band is present, independently of the IgM 
band result. 95%CI: confidence interval of 95%.
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with 99.6% sensitivity and 96.8% specificity12. The 
sensitivity and specificity reported here with the OnSite™ 
Leishmania IgG/IgM Combo test were lower than those 
previously reported in India. The differences may be due 
to antigen preparations, parasite genetic profiles prevalent 
in both regions and the population’s genetic diversity. The 
“OnSite™ Leishmania Ab Rapid” test as well as “Onsite™ 
Leishmania IgG/IgM Combo” test detects IgG and IgM 
antibodies. The difference is that the test evaluated here 
detects IgM and IgG in separate lines, while the other test 
detects both antibodies in the same line without distinction 
of these two subclasses of antibodies.
Although, both OnSite™ Leishmania IgG/IgM Combo 
and IT LEISH® are lateral flow immunochromatographic 
rapid tests based on the rK39, there are some structural 
differences in the cassettes. In the Onsite™ Leishmania 
IgG/IgM Combo, colloidal gold nanoparticles are 
functionalized with the rK39 while anti-human IgG 
and anti-human IgM antibodies constitute test lines 
on nitrocellulose membrane. On the other hand, in the 
IT LEISH® test, the rK39 antigen is placed on the test line 
while colloidal gold nanoparticles are functionalized with 
anti-human IgG antibodies. These differences could explain 
the variation observed between these two tests. 
Finally, rapid diagnostic tests may improve early VL 
detection, but their real-world performance varies, requiring 
local validation. In this first evaluation of the OnSite™ 
Leishmania IgG/IgM Combo in Brazil, the test performed 
satisfactorily, if minimum parameters are accepted. The 
presence of the IgM band, an innovation among the rapid 
tests for VL, at least in this study, was not associated with 
increased sensitivity, but with a false-positive reaction, thus 
requiring caution in its interpretation. 
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